Press release
Investigation announced for Investors in shares of Zogenix, Inc. (NASDAQ: ZGNX)
An investigation on behalf of investors in Zogenix, Inc. (NASDAQ: ZGNX) shares over potential wrongdoing at Zogenix, Inc.
Investors who purchased shares of Zogenix, Inc. (NASDAQ: ZGNX) and currently hold any of those NASDAQ: ZGNX shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Zogenix directors breached their fiduciary duties and caused damage to the company and its shareholders.
On April 12, 2019, a lawsuit was filed against Zogenix, Inc. (NASDAQ: ZGNX) over alleged violations of Federal Securities Laws.
The plaintiff claims that between February 6, 2019 and April 8, 2019, the Defendants made false and/or misleading statements and/or failed to disclose that Zogenix’s NDA for FINTEPLA contained inadequate non-clinical data and an incorrect version of a clinical dataset, that consequently, Zogenix’s NDA for FINTEPLA was unlikely to gain FDA approval, and that as a result, the Company’s public statements were materially false and misleading at all relevant times.
Those who purchased shares of Zogenix, Inc. (NASDAQ: ZGNX) have certain options and should contact the Shareholders Foundation.
Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Investors in shares of Zogenix, Inc. (NASDAQ: ZGNX) here
News-ID: 1875525 • Views: …
More Releases from Shareholders Foundation
Lawsuit Alert: Investors who lost money with James Hardie Industries plc (NYSE: …
An investor, who purchased shares of James Hardie Industries plc (NYSE: JHX), filed a lawsuit over alleged violations of Federal Securities Laws by James Hardie Industries plc in connection with certain allegedly false and misleading statements.
Investors who purchased shares of James Hardie Industries plc (NYSE: JHX) have certain options and for certain investors are short and strict deadlines running. Deadline: December 23, 2025. NYSE: JHX investors should contact the Shareholders…
Investigation announced for Long-Term Investors in SelectQuote, Inc. (NYSE: SLQT …
An investigation on behalf of current long-term investors in shares of SelectQuote, Inc. (NYSE: SLQT) concerning potential breaches of fiduciary duties by certain directors and officers of SelectQuote, Inc. was announced.
Investors who are current long term investors in SelectQuote, Inc. (NYSE: SLQT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term…
Lawsuit filed for Investors who lost money with shares of MoonLake Immunotherape …
An investor, who purchased shares of MoonLake Immunotherapeutics (NASDAQ: MLTX), filed a lawsuit over alleged violations of Federal Securities Laws by MoonLake Immunotherapeutics in connection with certain allegedly false and misleading statements.
Investors who purchased a significant amount of shares of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, have certain options and for certain investors are short and strict deadlines running. Deadline: December 15, 2025. NASDAQ:…
Dow Inc. (NYSE: DOW) Investor Alert: Deadline in Lawsuit on October 28, 2025
A deadline is coming up on October 28, 2025 in the lawsuit filed for certain investors of Dow Inc. (NYSE: DOW) over alleged securities laws violations by Dow Inc.
Investors who purchased shares of Dow Inc. (NYSE: DOW) have certain options and there are strict and short deadlines running. Deadline: October 28, 2025. Dow Inc. (NYSE: DOW) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -…
More Releases for Zogenix
Acute Repetitive Seizures Market SWOT Analysis by Leading Expert: Sunovion, Zoge …
The "Acute Repetitive Seizures Market" intelligence report, just published by USD Analytics Market, covers a micro-level study of important market niches, product offers, and sales channels. To determine market size, potential, growth trends, and competitive environment, the Acute Repetitive Seizures Market provides dynamic views. Both primary and secondary sources of data were used to generate the research, which has both qualitative and quantitative depth. Several of the major figures the…
Dravet Syndrome Treatment Market Is Booming Worldwide | Biocodex, Zogenix, Pfize …
The "Dravet Syndrome Treatment Market" intelligence report, just published by USD Analytics Market, covers a micro-level study of important market niches, product offers, and sales channels. to determine market size, potential, growth trends, and competitive environment, the Dravet Syndrome Treatment Market provides dynamic views. Both primary and secondary sources of data were used to generate the research, which has both qualitative and quantitative depth. Several of the major figures the…
Global Needleless Device Market Analysis, Competitors, Growth Rate 2023 | Zogeni …
Global Info Research announces the release of the report "Global Needleless Device Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029" . The report is a detailed and comprehensive analysis presented by region and country, type and application. As the market is constantly changing, the report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company…
Needle Free Injectior Market Growth by Top Most Key Players Zogenix,Inovio,Glide …
Needle Free Injectior Market
DataIntelo, 17-03-2020: The research report on the Needle Free Injectior Market is a deep analysis of the market. Experts have studied the historical data and compared it with the changing market situations. The report covers all the necessary information required by new entrants as well as the existing players to gain deeper insight.
Furthermore, the statistical survey in the report focuses on product specifications, costs, production capacities, marketing…
Investigation announced for long-term investors in shares of Zogenix, Inc. (NASD …
Certain directors of Zogenix, Inc are under investigation concerning potential breaches of fiduciary duties.
Investors who are current long term investors in Zogenix, Inc. (NASDAQ: ZGNX) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: ZGNX stocks follows a lawsuit filed against Zogenix, Inc. over alleged securities laws violations. The…
Dravet Syndrome Therapeutics- Pipeline Analysis 2018 | Zogenix, Inc., Ovid Thera …
Dravet syndrome is a form of severe myoclonic epilepsy that occurs in infants during their first year of age. If left untreated, it can be associated with other types of seizures, and status epilepticus. Children having Dravet syndrome are generally observed with poor cognitive skills and hyperactivity.
Download the sample report @ https://www.pharmaproff.com/request-sample/1098
It severely affects the person’s quality of life and around 10-20% of the patient are estimated to die due…
